Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis

Garske, L. A. and Bell, S. C. (2002) Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest, 121 4: 1363-1364. doi:10.1378/chest.121.4.1363


Author Garske, L. A.
Bell, S. C.
Title Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis
Journal name Chest   Check publisher's open access policy
ISSN 0012-3692
Publication date 2002-01-01
Sub-type Article (original research)
DOI 10.1378/chest.121.4.1363
Volume 121
Issue 4
Start page 1363
End page 1364
Total pages 2
Place of publication Northbrook, U.S.A.
Publisher American College of Chest Physicians
Language eng
Subject C1
321027 Respiratory Diseases
730110 Respiratory system and diseases (incl. asthma)
1103 Clinical Sciences
Abstract Hypertrophic pulmonary osteoarthropathy (HPOA) may complicate the advanced lung disease that is associated with cystic fibrosis, resulting in severe joint pain and early-morning stiffness. Symptoms are usually controlled with the administration of nonsteroidal anti-inflammatory drugs, physiotherapy, and, on occasions, oral corticosteroids. I This report describes a case of refractory HPOA with complete remission following the administration of IV pamidronate, which is a potent inhibitor of osteoclastic bone resorption. Symptom relief resulted for up to 3 months, but repeated courses of pamidronate have been required to maintain symptom control.
Keyword Respiratory System
Bone Pain
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 24 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 24 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 03:39:50 EST